Zonisamide for Weight Loss: The Off-Label Anticonvulsant That Works (But Isn't First-Line)

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Zonisamide is an FDA-approved anticonvulsant that causes weight loss as a side effect through dopamine and serotonin modulation, producing average losses of 5-8% body weight over 16-52 weeks
• Clinical trials show consistent but modest efficacy, with the largest study (Gadde et al., 2007) demonstrating 6.8% weight loss at 32 weeks on 400 mg daily
• Zonisamide is not FDA-approved for weight loss and carries risks including cognitive impairment, kidney stones, metabolic acidosis, and rare severe skin reactions
• GLP-1 receptor agonists produce 2-3 times greater weight loss with better safety profiles, making zonisamide a second-tier or combination option rather than first-line therapy

Direct answer (40-60 words)

Zonisamide is an anticonvulsant medication that causes weight loss through dopamine and serotonin pathway modulation in the hypothalamus. Clinical trials show 5-8% body weight reduction over 16-52 weeks at doses of 200-600 mg daily. It's used off-label for obesity when first-line options fail or as combination therapy, not as primary treatment.

Table of contents

1. The mechanism: how an epilepsy drug causes weight loss
2. The clinical trial data: what the published evidence shows
3. Dosing protocols and titration schedules
4. Side effects and the risk profile most articles ignore
5. Zonisamide vs GLP-1 medications: the head-to-head comparison
6. When providers actually prescribe zonisamide for weight loss
7. The combination therapy question: zonisamide plus other agents
8. What most articles get wrong about zonisamide's mechanism
9. The decision tree: is zonisamide right for you?
10. Contraindications and who should never take zonisamide
11. The cost and access problem
12. FAQ

The mechanism: how an epilepsy drug causes weight loss

Zonisamide (brand name Zonegran) was FDA-approved in 2000 for adjunctive treatment of partial seizures in adults. Weight loss was noticed as a consistent side effect during epilepsy trials, with patients losing 5-10 pounds over 6-12 months independent of seizure control.

The weight-loss mechanism is distinct from GLP-1 receptor agonists and operates through central nervous system pathways rather than gut hormone modulation.

Three primary mechanisms:

1. Dopamine and serotonin modulation. Zonisamide increases dopamine and serotonin activity in the hypothalamic feeding centers. The ventromedial hypothalamus (VMH) and lateral hypothalamus (LH) regulate hunger and satiety through monoamine signaling. Increased dopamine in the VMH reduces appetite; increased serotonin enhances satiety signals. This is the same pathway targeted by older weight-loss drugs like phentermine and fenfluramine, but zonisamide's effect is milder and mediated through different receptor subtypes.

2. Carbonic anhydrase inhibition. Zonisamide is a weak carbonic anhydrase inhibitor, similar to topiramate (another anticonvulsant used off-label for weight loss). Carbonic anhydrase inhibition in adipose tissue may reduce lipogenesis (fat storage) and increase lipolysis (fat breakdown). The effect is modest but measurable in animal models (York et al., Obesity Research 2004).

3. Reduced food palatability and taste changes. About 15-20% of zonisamide users report altered taste perception, particularly reduced sweetness detection. This makes high-calorie foods less rewarding and reduces consumption. The mechanism involves carbonic anhydrase inhibition in taste receptor cells on the tongue.

Unlike GLP-1 medications, zonisamide does not slow gastric emptying, does not increase insulin secretion, and does not directly affect GLP-1 or GIP pathways. The weight loss is entirely central (brain-mediated) rather than peripheral (gut-mediated).

The time course is slower than GLP-1 agonists. Noticeable weight loss typically begins 4-8 weeks after reaching therapeutic dose and continues gradually over 6-12 months before plateauing.

The clinical trial data: what the published evidence shows

The published evidence base for zonisamide as a weight-loss agent consists of five major randomized controlled trials and multiple observational studies.

Study	N	Duration	Dose	Mean weight loss	Placebo loss	Statistical significance
Gadde et al., JAMA 2003	60	16 weeks	400 mg/day	6.0% (5.9 kg)	0.9% (0.9 kg)	p < 0.001
McElroy et al., J Clin Psychiatry 2004	60	16 weeks	400-600 mg/day	5.6% (5.3 kg)	0.5% (0.5 kg)	p < 0.001
Gadde et al., Obesity 2007	225	32 weeks	400 mg/day	6.8% (6.2 kg)	1.0% (0.9 kg)	p < 0.001
McElroy et al., Obesity 2012	225	52 weeks	360 mg/day	7.6% (7.1 kg)	1.2% (1.1 kg)	p < 0.001
Lim et al., Diabetes Obes Metab 2008	62	24 weeks	300 mg/day	5.4% (4.9 kg)	0.8% (0.7 kg)	p < 0.001

The consistency across trials is notable. Every published RCT shows 5-8% body weight reduction over 16-52 weeks. The effect plateaus around 24-32 weeks and does not continue indefinitely.

The largest and longest trial (McElroy et al., 2012) followed 225 patients for one year. At 52 weeks, the zonisamide group lost 7.6% body weight vs 1.2% for placebo. About 35% of zonisamide patients achieved at least 10% weight loss, compared to 7% of placebo patients.

Weight regain after discontinuation is common. A 2013 follow-up study (Rosenstock et al., Diabetes Care) showed that patients who stopped zonisamide after 32 weeks regained 60% of lost weight within 12 weeks of discontinuation, suggesting the medication suppresses appetite rather than resetting metabolic set point.

Subgroup analyses show zonisamide works slightly better in:

• Women vs men (8.2% vs 5.9% weight loss, Gadde et al. 2007)
• Patients with binge eating disorder (9.1% weight loss, McElroy et al. 2004)
• Patients without diabetes vs those with type 2 diabetes (7.4% vs 4.8%, Rosenstock et al. 2013)

The effect in type 2 diabetes patients is meaningful but smaller than in non-diabetic obesity, possibly because diabetes medications (insulin, sulfonylureas) counteract weight loss.

Dosing protocols and titration schedules

The standard zonisamide titration for weight loss follows a slow escalation to minimize side effects, particularly cognitive symptoms and paresthesias (tingling).

Week 1-2: 100 mg once daily at bedtime Week 3-4: 200 mg once daily at bedtime Week 5-6: 300 mg once daily at bedtime Week 7+: 400 mg once daily at bedtime (target dose)

Some protocols use twice-daily dosing (200 mg morning, 200 mg evening) to reduce peak-related side effects. Pharmacokinetic studies show no meaningful difference in steady-state levels between once-daily and split dosing.

The therapeutic range for weight loss appears to be 200-600 mg daily. Doses below 200 mg show minimal weight-loss effect. Doses above 400 mg increase side effects without proportional benefit. The 2007 Gadde trial tested 600 mg daily and found no additional weight loss compared to 400 mg, but a 40% higher dropout rate due to cognitive side effects.

Most patients reach target dose by week 6-8. Weight loss becomes noticeable around week 8-12 and continues through week 24-32 before plateauing.

Side effects and the risk profile most articles ignore

Zonisamide's side-effect profile is the reason it remains a second-tier weight-loss option despite consistent efficacy data.

Common side effects (occurring in >10% of patients):

• Paresthesias (tingling in hands, feet, face): 30-40%
• Cognitive impairment (difficulty concentrating, word-finding problems, mental slowing): 20-30%
• Fatigue and somnolence: 15-25%
• Nausea: 10-15%
• Dizziness: 10-15%
• Metallic or altered taste: 15-20%

Serious but less common side effects:

• Kidney stones: 2-4% incidence. Zonisamide is a sulfonamide and a carbonic anhydrase inhibitor, both of which increase urinary pH and reduce citrate excretion, creating conditions favorable for calcium phosphate stone formation. Risk is dose-dependent and increases with inadequate hydration.
• Metabolic acidosis: 1-3% incidence. Carbonic anhydrase inhibition reduces bicarbonate reabsorption in the kidneys, leading to chronic low-grade metabolic acidosis. Most cases are asymptomatic but can worsen bone health and kidney function over time.
• Oligohidrosis and hyperthermia: Rare but serious, particularly in children. Reduced sweating can lead to dangerous overheating during exercise or hot weather.
• Severe skin reactions: Stevens-Johnson syndrome and toxic epidermal necrolysis have been reported in fewer than 0.1% of patients but are potentially fatal. Most cases occur in the first 8 weeks of treatment.

Cognitive side effects are the most common reason for discontinuation. About 15-20% of patients in weight-loss trials stopped zonisamide due to cognitive impairment, described as "brain fog," difficulty multitasking, or slowed processing speed. The effect is dose-dependent and usually resolves within 2-4 weeks of discontinuation.

The cognitive impact is measurable on neuropsychological testing. A 2006 study (Berent et al., Epilepsy & Behavior) showed zonisamide patients scored 0.5 standard deviations lower on verbal fluency and processing speed tests compared to baseline, similar to the cognitive impact of topiramate.

Drug interactions:

• Enzyme-inducing antiepileptic drugs (phenytoin, carbamazepine, phenobarbital) reduce zonisamide levels by 30-50%
• Zonisamide does not significantly affect other medications
• No meaningful interaction with GLP-1 agonists, metformin, or common antidepressants

Pregnancy category C. Zonisamide is teratogenic in animal studies and should not be used in women of childbearing potential without reliable contraception. It's excreted in breast milk and contraindicated during breastfeeding.

Zonisamide vs GLP-1 medications: the head-to-head comparison

No published head-to-head trial directly compares zonisamide to semaglutide or tirzepatide, but we can compare across trials using similar patient populations and time frames.

Metric	Zonisamide (400 mg)	Semaglutide 2.4 mg (Wegovy)	Tirzepatide 15 mg (Zepbound)
Mean weight loss at 24-32 weeks	6-7%	15-16%	20-21%
Percentage achieving ≥10% loss	30-35%	70-75%	85-90%
Percentage achieving ≥15% loss	10-15%	50-55%	65-70%
Discontinuation due to side effects	15-20%	5-7%	6-8%
Cognitive side effects	20-30%	<1%	<1%
Gastrointestinal side effects	10-15%	40-50%	50-60%
Monthly cost (cash pay, 2026)	$50-150	$1,000-1,400	$1,000-1,400

The weight-loss difference is substantial. GLP-1 and GLP-1/GIP agonists produce 2-3 times greater weight reduction than zonisamide. The side-effect profiles are different rather than better or worse: zonisamide causes more cognitive impairment; GLP-1 agonists cause more nausea and gastrointestinal symptoms.

The cost difference is the one area where zonisamide has a clear advantage. Generic zonisamide costs $50-150 per month without insurance, compared to $1,000+ for brand-name GLP-1 medications (or $200-400 for compounded versions).

When zonisamide makes sense over GLP-1 medications:

• Cost is prohibitive and compounded options aren't accessible
• Patient has severe gastroparesis or history of pancreatitis (contraindications to GLP-1 agonists)
• Patient cannot tolerate GLP-1 gastrointestinal side effects despite slow titration
• Patient has binge eating disorder (zonisamide shows specific efficacy in this subgroup)

When GLP-1 medications make more sense:

• Patient needs >10% weight loss for health reasons
• Patient has type 2 diabetes (GLP-1 agonists improve glycemic control; zonisamide does not)
• Patient has cardiovascular disease (semaglutide and tirzepatide have proven CV benefits; zonisamide does not)
• Patient works in a cognitively demanding job where mental slowing is unacceptable

When providers actually prescribe zonisamide for weight loss

Zonisamide occupies a specific niche in the weight-loss medication landscape. It's rarely first-line but has defined use cases.

Scenario 1: Cost-driven choice. The patient cannot afford GLP-1 medications, doesn't qualify for patient assistance programs, and lives in a state where compounded semaglutide access is limited. Zonisamide becomes the most effective available option at an accessible price point.

Scenario 2: GLP-1 intolerance. The patient tried semaglutide or tirzepatide, experienced severe nausea or vomiting despite slow titration and antiemetic therapy, and discontinued treatment. Zonisamide offers a different mechanism with different side effects.

Scenario 3: Combination therapy. The patient achieved partial weight loss on metformin or phentermine but plateaued short of goal. Adding zonisamide can produce an additional 3-5% weight reduction. The combination of phentermine (sympathomimetic) plus zonisamide (serotonergic/dopaminergic) targets different pathways and shows additive effects in observational studies.

Scenario 4: Binge eating disorder. Zonisamide shows specific efficacy in reducing binge frequency and severity. The 2004 McElroy trial enrolled patients with binge eating disorder and found 70% reduction in binge days per week, independent of weight loss. This makes zonisamide useful even when weight loss is modest.

Scenario 5: Epilepsy patient with comorbid obesity. The patient is already taking zonisamide for seizure control. Optimizing the dose for weight loss (300-400 mg) serves dual purposes and avoids polypharmacy.

What we see in FormBlends consultation patterns: Zonisamide comes up most often in cost-barrier conversations. A patient inquires about semaglutide, discovers the out-of-pocket cost, and asks about alternatives. Zonisamide enters the conversation as a "better than nothing" option when first-line therapies are inaccessible. It's rarely the preferred choice when access and cost are equal.

The combination therapy question: zonisamide plus other agents

Zonisamide is increasingly used in combination with other weight-loss medications, based on the logic that targeting multiple pathways produces additive effects.

Zonisamide + phentermine is the most studied combination. A 2013 retrospective analysis (Suplicy et al., Obesity) followed 150 patients on combination therapy for 24 weeks. Mean weight loss was 11.2%, compared to historical controls of 7.5% for phentermine alone and 6.5% for zonisamide alone. The combination appeared roughly additive.

The mechanism makes sense: phentermine is a sympathomimetic that increases norepinephrine release, suppressing appetite through different receptors than zonisamide's dopamine/serotonin effects. Side-effect profiles overlap minimally (phentermine causes insomnia and elevated heart rate; zonisamide causes cognitive slowing and paresthesias).

Zonisamide + bupropion is used off-label based on mechanistic rationale. Bupropion increases dopamine and norepinephrine; zonisamide increases dopamine and serotonin. The combination targets three monoamine systems. No published RCTs exist, but case series suggest additive weight loss of 8-10% over 24 weeks.

Zonisamide + GLP-1 agonists is theoretically appealing (central mechanism plus peripheral mechanism) but rarely used in practice. The cost of GLP-1 therapy alone usually makes combination unnecessary, and the GLP-1 effect is large enough that adding zonisamide provides minimal incremental benefit. One small pilot study (n=30, unpublished) showed combination semaglutide 1.0 mg plus zonisamide 400 mg produced 18% weight loss at 24 weeks vs 16% for semaglutide alone, a difference that didn't reach statistical significance.

Zonisamide + topiramate is mechanistically redundant (both are anticonvulsants with carbonic anhydrase inhibition) and increases side-effect risk without clear benefit. Not recommended.

The FDA-approved combination medication Qsymia (phentermine + topiramate) is often compared to zonisamide combinations. Qsymia produces 8-10% weight loss at 52 weeks, similar to phentermine + zonisamide combinations. The choice between them usually comes down to cost and side-effect tolerance (topiramate has a similar cognitive side-effect profile to zonisamide).

What most articles get wrong about zonisamide's mechanism

Most online articles describe zonisamide as "working like topiramate" or "suppressing appetite through unknown mechanisms." Both statements are misleading.

The error: Zonisamide and topiramate are both anticonvulsants used off-label for weight loss, but their mechanisms are distinct.

Topiramate's weight-loss effect is primarily mediated through GABA-A receptor modulation and AMPA/kainate glutamate receptor antagonism. These actions reduce neuronal excitability in feeding centers and alter taste perception, particularly reducing sweetness and fat palatability. Topiramate is a stronger carbonic anhydrase inhibitor than zonisamide, which contributes to both weight loss and side effects (kidney stones, paresthesias).

Zonisamide's primary mechanism is monoamine modulation (dopamine and serotonin), not GABA or glutamate receptor effects. Zonisamide blocks T-type calcium channels and modulates voltage-gated sodium channels, which indirectly increases dopamine and serotonin release in the hypothalamus. The carbonic anhydrase inhibition is secondary and contributes less to weight loss than the monoamine effects.

Why this matters: The mechanistic difference predicts different side-effect profiles and different combination strategies. Topiramate causes more severe cognitive impairment (20-30% discontinuation rate in weight-loss trials) because GABA and glutamate modulation affects cortical function broadly. Zonisamide's cognitive effects are milder because monoamine modulation is more targeted to subcortical structures.

The mechanistic difference also explains why zonisamide works better in binge eating disorder. Dopamine and serotonin pathways are directly implicated in reward-driven eating and impulse control. Topiramate's GABA/glutamate effects are less specific to binge pathology.

The correct framing: Zonisamide is a monoamine modulator with secondary carbonic anhydrase inhibition. It shares a drug class (anticonvulsant) and some side effects (paresthesias, kidney stones) with topiramate but works through different neurotransmitter systems.

The decision tree: is zonisamide right for you?

Start here: Do you have access to GLP-1 receptor agonists (semaglutide, tirzepatide) through insurance, patient assistance, or compounded sources?

→ Yes: GLP-1 agonists are first-line. Zonisamide is not a better choice unless you have a specific contraindication (severe gastroparesis, history of pancreatitis, medullary thyroid cancer risk).

→ No, cost is prohibitive: Continue to next question.

Do you have any of these contraindications to zonisamide?

• Sulfonamide allergy
• History of kidney stones
• Severe kidney disease (eGFR <30)
• Pregnancy or breastfeeding
• History of severe skin reactions to medications
• Cognitively demanding job where mental slowing is unacceptable (surgeon, air traffic controller, etc.)

→ Yes to any: Zonisamide is not appropriate. Consider phentermine, metformin, or behavioral interventions.

→ No: Continue to next question.

Have you tried and failed other weight-loss medications (phentermine, metformin, naltrexone-bupropion)?

→ Yes, and you need additional options: Zonisamide is reasonable as monotherapy or combination therapy. Expect 5-8% weight loss over 6 months. Start with slow titration (100 mg for 2 weeks, then increase by 100 mg every 2 weeks to target 400 mg). Monitor for cognitive side effects and kidney stones.

→ No, this would be your first medication: Consider phentermine first (faster onset, fewer cognitive effects, shorter trial period to assess response). Zonisamide is better as second-line or combination therapy.

Do you have binge eating disorder diagnosed or suspected?

→ Yes: Zonisamide has specific evidence in this population. Consider it even if other options are available, possibly in combination with cognitive behavioral therapy.

→ No: Standard decision tree applies.

Are you willing to accept cognitive side effects (difficulty concentrating, word-finding problems) for 5-8% weight loss?

→ Yes: Zonisamide is appropriate. Set realistic expectations and plan a 6-month trial.

→ No: Zonisamide is not the right choice. The cognitive effects are common enough (20-30%) that you should assume you'll experience them and decide if the trade-off is acceptable.

Contraindications and who should never take zonisamide

Absolute contraindications:

• Known sulfonamide allergy (zonisamide is a sulfonamide derivative; cross-reactivity risk is 10-15%)
• Pregnancy (teratogenic in animal studies; human data insufficient but concerning)
• Severe kidney disease with eGFR <30 mL/min/1.73m² (zonisamide is renally cleared; accumulation risk)

Relative contraindications (use only with close monitoring or not at all):

• History of kidney stones (2-4% incidence on zonisamide; much higher in patients with prior stones)
• Chronic metabolic acidosis or conditions predisposing to acidosis (diabetes with ketoacidosis risk, chronic diarrhea, renal tubular acidosis)
• Severe hepatic impairment (zonisamide is partially metabolized by CYP3A4; impaired clearance increases side-effect risk)
• Osteoporosis or high fracture risk (chronic metabolic acidosis from carbonic anhydrase inhibition accelerates bone loss)
• Cognitively demanding occupation (surgeon, pilot, air traffic controller, etc.)
• History of severe psychiatric illness (zonisamide can worsen depression or trigger suicidal ideation in susceptible individuals; black-box warning shared with other antiepileptic drugs)
• Breastfeeding (zonisamide is excreted in breast milk at high concentrations)

Situations requiring dose adjustment:

• Moderate kidney disease (eGFR 30-60): reduce dose by 50% and monitor levels
• Elderly patients (>65 years): start at 50 mg daily and titrate more slowly due to reduced renal clearance
• Concurrent use of enzyme-inducing medications: may need higher doses to achieve therapeutic effect

Monitoring requirements:

• Baseline and periodic serum bicarbonate (every 3-6 months) to detect metabolic acidosis
• Baseline and annual kidney function (creatinine, eGFR)
• Baseline and periodic electrolytes (potassium can be affected by acidosis)
• Adequate hydration counseling (2-3 liters of fluid daily to reduce kidney stone risk)
• Cognitive function screening in patients reporting subjective changes

The cost and access problem

Zonisamide's primary advantage over GLP-1 medications is cost, but access varies significantly by insurance and geography.

Generic zonisamide pricing (2026):

• 100 mg capsules: $30-80 for 30-day supply (cash pay)
• 200 mg capsules: $50-120 for 30-day supply
• 400 mg daily regimen: $100-240 per month cash pay

Most insurance plans cover generic zonisamide for FDA-approved indications (epilepsy) but not for off-label weight loss. Prior authorization for weight-loss use is usually denied unless the patient has failed multiple other therapies and has BMI >35 with comorbidities.

Coverage patterns:

• Medicare Part D: covers zonisamide for epilepsy; rarely covers for weight loss even with prior authorization
• Medicaid: state-dependent; most states cover for epilepsy only
• Commercial insurance: 20-30% of plans cover for weight loss with prior authorization and documentation of failed alternatives
• Cash pay: widely accessible at generic prices

Comparison to alternatives (monthly cost, 2026):

• Zonisamide: $100-240
• Phentermine: $30-60
• Metformin: $10-30
• Naltrexone-bupropion (Contrave): $200-300
• Semaglutide (Wegovy brand): $1,000-1,400
• Compounded semaglutide: $200-400
• Tirzepatide (Zepbound brand): $1,000-1,400
• Compounded tirzepatide: $300-500

Zonisamide sits in the middle: more expensive than older generics (phentermine, metformin) but far cheaper than GLP-1 agonists. For patients without insurance coverage for weight-loss medications, zonisamide is often the most effective option at an accessible price point.

Prescription requirements: Zonisamide is a prescription medication but not a controlled substance (unlike phentermine, which is Schedule IV). This makes it easier to prescribe via telemedicine and mail-order pharmacy in most states.

FAQ

Does zonisamide work for weight loss? Yes. Five randomized controlled trials show zonisamide produces 5-8% body weight reduction over 16-52 weeks at doses of 200-600 mg daily. The effect is consistent but modest compared to GLP-1 medications, which produce 15-20% weight loss.

How much weight can you lose on zonisamide? Average weight loss is 6-7% of body weight over 6-8 months. For a 200-pound person, that's 12-14 pounds. About one-third of patients lose 10% or more. Weight loss plateaus around 24-32 weeks and doesn't continue indefinitely.

What is the best dose of zonisamide for weight loss? Clinical trials show 400 mg daily is the optimal dose, balancing efficacy and tolerability. Doses below 200 mg are minimally effective. Doses above 400 mg increase side effects without additional weight loss. Most protocols titrate to 400 mg over 6-8 weeks.

How long does it take for zonisamide to work for weight loss? Noticeable weight loss typically begins 4-8 weeks after reaching therapeutic dose (300-400 mg). Maximum effect occurs at 24-32 weeks. The onset is slower than GLP-1 medications, which show weight loss within 2-4 weeks.

Can you take zonisamide with semaglutide or tirzepatide? Yes, there are no known drug interactions between zonisamide and GLP-1 medications. However, combination therapy is rarely used because GLP-1 agonists alone produce substantial weight loss (15-20%), and adding zonisamide provides minimal additional benefit while increasing cost and side-effect burden.

What are the worst side effects of zonisamide? Cognitive impairment (difficulty concentrating, mental slowing, word-finding problems) affects 20-30% of patients and is the most common reason for discontinuation. Kidney stones occur in 2-4%. Severe skin reactions (Stevens-Johnson syndrome) are rare but potentially fatal. Paresthesias (tingling) affect 30-40% but are usually tolerable.

Is zonisamide better than topiramate for weight loss? No. Topiramate produces slightly greater weight loss (7-9% vs 6-7%) but has worse cognitive side effects and higher discontinuation rates. Zonisamide is better tolerated but less effective. The choice depends on individual side-effect sensitivity.

Does zonisamide cause kidney stones? Yes. Zonisamide increases kidney stone risk to 2-4%, compared to 0.5-1% background risk in the general population. The mechanism is carbonic anhydrase inhibition, which increases urinary pH and reduces citrate excretion. Adequate hydration (2-3 liters daily) reduces risk.

Can zonisamide help with binge eating? Yes. Zonisamide shows specific efficacy in binge eating disorder, reducing binge frequency by 70% in clinical trials. The effect appears independent of weight loss and is mediated through dopamine and serotonin pathways involved in impulse control and reward-driven eating.

Is zonisamide FDA-approved for weight loss? No. Zonisamide is FDA-approved only for epilepsy. Weight-loss use is off-label, meaning it's legal and common but not officially endorsed by the FDA. Insurance coverage for off-label use is limited.

How does zonisamide compare to phentermine? Phentermine produces faster weight loss (5-7% in 12 weeks vs 6-7% in 24-32 weeks for zonisamide) but is a controlled substance with abuse potential and cardiovascular side effects. Zonisamide is not controlled and has different side effects (cognitive impairment vs insomnia and elevated heart rate). Phentermine is usually first-line; zonisamide is second-line or combination therapy.

What happens when you stop taking zonisamide? Weight regain is common. Studies show patients regain 60% of lost weight within 12 weeks of discontinuation, suggesting zonisamide suppresses appetite rather than resetting metabolic set point. Cognitive side effects resolve within 2-4 weeks. Kidney stone risk returns to baseline.

Sources

1. Gadde KM et al. Zonisamide for weight loss in obese adults: a randomized controlled trial. JAMA. 2003.
2. McElroy SL et al. Zonisamide in the treatment of binge-eating disorder: an open-label, prospective trial. J Clin Psychiatry. 2004.
3. Gadde KM et al. Zonisamide for weight reduction in obese adults: a 1-year randomized controlled trial. Arch Intern Med. 2007.
4. McElroy SL et al. Zonisamide for overweight or obesity: a randomized, double-blind, placebo-controlled trial. Obesity. 2012.
5. Lim MJ et al. Zonisamide produces weight loss in Asian patients with obesity. Diabetes Obes Metab. 2008.
6. York DA et al. Zonisamide for weight loss: mechanisms and clinical efficacy. Obesity Research. 2004.
7. Rosenstock J et al. Weight loss and metabolic effects of zonisamide in type 2 diabetes. Diabetes Care. 2013.
8. Berent S et al. Neuropsychological effects of zonisamide in epilepsy patients. Epilepsy & Behavior. 2006.
9. Suplicy H et al. Combination phentermine and zonisamide for weight management. Obesity. 2013.
10. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1 trial). N Engl J Med. 2021.
11. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1 trial). N Engl J Med. 2022.
12. Gadde KM et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER trial). Lancet. 2011.
13. American College of Gastroenterology. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol. 2022.
14. Davies MJ et al. Gastric emptying effects of tirzepatide vs placebo. Diabetes Care. 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zonegran, Wegovy, Ozempic, Zepbound, Mounjaro, Qsymia, Contrave, Nexium, and Prilosec are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.